{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:09:45Z","timestamp":1790622585598,"version":"4.1.0"},"reference-count":38,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JND"],"published-print":{"date-parts":[[2021,9,14]]},"abstract":"<jats:p>Background: Edasalonexent (CAT-1004) is an orally-administered novel small molecule drug designed to inhibit NF-\u03baB and potentially reduce inflammation and fibrosis to improve muscle function and thereby slow disease progression and muscle decline in Duchenne muscular dystrophy (DMD). Objective: This international, randomized 2\u200a:\u200a1, placebo-controlled, phase 3 study in patients \u22654\u200a\u2013\u200a&lt;\u200a8 years old with DMD due to any dystrophin mutation examined the effect of edasalonexent (100\u200amg\/kg\/day) compared to placebo over 52 weeks. Methods: Endpoints were changes in the North Star Ambulatory Assessment (NSAA; primary) and timed function tests (TFTs; secondary). Assessment of health-related function used the Pediatric Outcomes Data Collection tool (PODCI). Results: One hundred thirty one patients received edasalonexent (n\u200a=\u200a88) and placebo (n\u200a=\u200a43). At week 52, differences between edasalonexent and placebo for NSAA total score and TFTs were not statistically significant, although there were consistently less functional declines in the edasalonexent group. A pre-specified analysis by age demonstrated that younger patients (\u22646.0 years) showed more robust and statistically significant differences between edasalonexent and placebo for some assessments. Treatment was well-tolerated and the majority of adverse events were mild, and most commonly involved the gastrointestinal system (primarily diarrhea). Conclusions: Edasalonexent was generally well-tolerated with a manageable safety profile at the dose of 100\u200amg\/kg\/day. Although edasalonexent did not achieve statistical significance for improvement in primary and secondary functional endpoints for assessment of DMD, subgroup analysis suggested that edasalonexent may slow disease progression if initiated before 6 years of age. (NCT03703882)<\/jats:p>","DOI":"10.3233\/jnd-210689","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T10:44:16Z","timestamp":1623408256000},"page":"769-784","source":"Crossref","is-referenced-by-count":31,"title":["A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial"],"prefix":"10.1177","volume":"8","author":[{"given":"Richard S.","family":"Finkel","sequence":"first","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital, Memphis, TN and Nemours Children\u2019s Hospital, Orlando, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"(For the PolarisDMD Study Group)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig M.","family":"McDonald","sequence":"additional","affiliation":[{"name":"University of California at Davis, Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lee Sweeney","sequence":"additional","affiliation":[{"name":"University of Florida College of Medicine, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Finanger","sequence":"additional","affiliation":[{"name":"Shriners Hospital for Children, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Neil Knierbein","sequence":"additional","affiliation":[{"name":"University of Michigan, MI, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn R.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Kennedy Krieger Institute, The Johns Hopkins School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine D.","family":"Mathews","sequence":"additional","affiliation":[{"name":"University of Iowa Carver College of Medicine, Iowa City, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Marks","sequence":"additional","affiliation":[{"name":"Cook Children\u2019s Medical Center, Fort Worth, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Statland","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center, Kansas City, KS, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Nance","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh J.","family":"McMillan","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Eastern Ontario, Ottawa, CA, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"McCullagh","sequence":"additional","affiliation":[{"name":"Royal Manchester Children\u2019s Hospital, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuixia","family":"Tian","sequence":"additional","affiliation":[{"name":"Cincinnati Children\u2019s Hospital & University of Cincinnati, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique M.","family":"Ryan","sequence":"additional","affiliation":[{"name":"Royal Children\u2019s Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan","family":"O\u2019Rourke","sequence":"additional","affiliation":[{"name":"Children\u2019s Health Ireland at Temple Street, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"M\u00fcller-Felber","sequence":"additional","affiliation":[{"name":"Dr. v. Haunersches Kinderspital, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Tulinius","sequence":"additional","affiliation":[{"name":"Queen Silvia Children\u2019s Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Bryan","family":"Burnette","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cam-Tu","family":"Nguyen","sequence":"additional","affiliation":[{"name":"CHU Sainte-Justine, Montreal, CA, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayal","family":"Vijayakumar","sequence":"additional","affiliation":[{"name":"Bristol Children\u2019s Hospital, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessika","family":"Johannsen","sequence":"additional","affiliation":[{"name":"University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han C.","family":"Phan","sequence":"additional","affiliation":[{"name":"Rare Disease Research, LLC, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Eagle","sequence":"additional","affiliation":[{"name":"Atom International Limited, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"MacDougall","sequence":"additional","affiliation":[{"name":"University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mancini","sequence":"additional","affiliation":[{"name":"Catabasis Pharmaceuticals, Inc., Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne M.","family":"Donovan","sequence":"additional","affiliation":[{"name":"Catabasis Pharmaceuticals, Inc., Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JND-210689_ref1","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.nmd.2014.03.008","article-title":"A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy","volume":"24","author":"Mah","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"10.3233\/JND-210689_ref2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.rehab.2013.06.002","article-title":"Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011","volume":"56","author":"Kieny","year":"2013","journal-title":"Ann Phys Rehabil Med"},{"key":"10.3233\/JND-210689_ref4","doi-asserted-by":"crossref","first-page":"e90341","DOI":"10.1172\/jci.insight.90341","article-title":"Disease-modifying effects of orally bioavailable NF-kappaB inhibitors in dystrophin-deficient muscle","volume":"1","author":"Hammers","year":"2016","journal-title":"JCI Insight"},{"key":"10.3233\/JND-210689_ref5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2044-5040-4-18","article-title":"NBD delivery improves the disease phenotype of the golden retriever model of Duchenne muscular dystrophy","volume":"4","author":"Kornegay","year":"2014","journal-title":"Skelet Muscle"},{"key":"10.3233\/JND-210689_ref6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1096\/fj.02-0542com","article-title":"Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy","volume":"17","author":"Kumar","year":"2003","journal-title":"FASEB J"},{"key":"10.3233\/JND-210689_ref7","doi-asserted-by":"crossref","first-page":"299rv4","DOI":"10.1126\/scitranslmed.aaa7322","article-title":"Immune-mediated pathology in Duchenne muscular dystrophy","volume":"7","author":"Rosenberg","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.3233\/JND-210689_ref8","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1016\/j.biocel.2013.05.001","article-title":"Wasting mechanisms in muscular dystrophy","volume":"45","author":"Shin","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"10.3233\/JND-210689_ref9","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1172\/JCI30556","article-title":"Interplay of IKK\/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy","volume":"117","author":"Acharyya","year":"2007","journal-title":"J Clin Invest"},{"key":"10.3233\/JND-210689_ref10","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00109-008-0373-8","article-title":"Nuclear factor-kappa B signaling in skeletal muscle atrophy","volume":"86","author":"Li","year":"2008","journal-title":"J Mol Med (Berl)"},{"key":"10.3233\/JND-210689_ref11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/B978-0-12-385940-2.00004-8","article-title":"NF-kappaB signaling in skeletal muscle health and disease","volume":"96","author":"Peterson","year":"2011","journal-title":"Curr Top Dev Biol"},{"key":"10.3233\/JND-210689_ref12","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/mus.24607","article-title":"Musculoskeletal simulation can help explain selective muscle degeneration in Duchenne muscular dystrophy","volume":"52","author":"Hu","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.3233\/JND-210689_ref13","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/hmg\/ddg197","article-title":"Dissection of temporal gene expression signatures of affected and spared muscle groups in dystrophin-deficient (mdx) mice","volume":"12","author":"Porter","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JND-210689_ref14","doi-asserted-by":"crossref","first-page":"e106435","DOI":"10.1371\/journal.pone.0106435","article-title":"Magnetic resonance imaging and spectroscopy assessment of lower extremity skeletal muscles in boys with Duchenne muscular dystrophy: a multicenter cross sectional study","volume":"9","author":"Forbes","year":"2014","journal-title":"PLoS One"},{"key":"10.3233\/JND-210689_ref15","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1021\/acs.jmedchem.5b01961","article-title":"Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid","volume":"59","author":"Vu","year":"2016","journal-title":"J Med Chem"},{"key":"10.3233\/JND-210689_ref16","doi-asserted-by":"crossref","first-page":"e97957","DOI":"10.1371\/journal.pone.0097957","article-title":"Omega-3 free fatty acids suppress macrophage inflammasome activation by inhibiting NF-kappaB activation and enhancing autophagy","volume":"9","author":"Williams-Bey","year":"2014","journal-title":"PLoS One"},{"key":"10.3233\/JND-210689_ref17","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1359\/jbmr.091041","article-title":"Capacity of omega-3 fatty acids or eicosapentaenoic acid to counteract weightlessness-induced bone loss by inhibiting NF-kappaB activation: from cells to bed rest to astronauts","volume":"25","author":"Zwart","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.3233\/JND-210689_ref18","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.8052854","article-title":"Inhibition of NF-kappa B by sodium salicylate and aspirin","volume":"265","author":"Kopp","year":"1994","journal-title":"Science"},{"key":"10.3233\/JND-210689_ref19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/23948","article-title":"The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta","volume":"396","author":"Yin","year":"1998","journal-title":"Nature"},{"key":"10.3233\/JND-210689_ref20","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jcph.842","article-title":"A Novel NF-kappaB Inhibitor, Edasalonexent (CAT-in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects","volume":"57","author":"Donovan","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.3233\/JND-210689_ref21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3233\/JND-180341","article-title":"Phase 1 Study of Edasalonexent (CAT-an Oral NF-kappaB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy","volume":"6","author":"Finanger","year":"2019","journal-title":"J Neuromuscul Dis"},{"issue":"5","key":"10.3233\/JND-210689_ref22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.nmd.2021.02.001","article-title":"Disease- modifying effects of edasalonexent, an NF - \u03baB inhibitor, in young boys with Duchenne muscular dystrophy: R esults of the MoveDMD phase 2 and open label extension trial","volume":"31","author":"Finkel","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.3233\/JND-210689_ref23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/pri.520","article-title":"Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy","volume":"17","author":"Scott","year":"2012","journal-title":"Physiother Res Int"},{"key":"10.3233\/JND-210689_ref25","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.nmd.2019.09.010","article-title":"Longitudinal natural history in young boys with Duchenne muscular dystrophy","volume":"29","author":"Coratti","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.3233\/JND-210689_ref26","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.4155\/cli.11.113","article-title":"Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings","volume":"1","author":"Bushby","year":"2011","journal-title":"Clinical investigation"},{"key":"10.3233\/JND-210689_ref27","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.nmd.2010.06.014","article-title":"North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy","volume":"20","author":"Mazzone","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"10.3233\/JND-210689_ref28","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1460-6984.2012.00197.x","article-title":"Dysphagia in Duchenne muscular dystrophy assessed by validated questionnaire","volume":"48","author":"Archer","year":"2013","journal-title":"Int J Lang Commun Disord"},{"key":"10.3233\/JND-210689_ref29","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1172\/JCI28721","article-title":"Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration","volume":"116","author":"Mourkioti","year":"2006","journal-title":"J Clin Invest"},{"key":"10.3233\/JND-210689_ref30","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.clinthera.2014.04.011","article-title":"A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy","volume":"36","author":"Peay","year":"2014","journal-title":"Clin Ther"},{"key":"10.3233\/JND-210689_ref32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12883-019-1304-8","article-title":"Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne Registry","volume":"19","author":"Cowen","year":"2019","journal-title":"BMC Neurol"},{"key":"10.3233\/JND-210689_ref33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/JND-140053","article-title":"Compliance to Care Guidelines for Duchenne Muscular Dystrophy","volume":"2","author":"Landfeldt","year":"2015","journal-title":"J Neuromuscul Dis"},{"key":"10.3233\/JND-210689_ref34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pediatrneurol.2020.08.013","article-title":"Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests","volume":"113","author":"Miller","year":"2020","journal-title":"Pediatr Neurol"},{"key":"10.3233\/JND-210689_ref35","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1469-8749.2011.03939.x","article-title":"Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy","volume":"53","author":"Mayhew","year":"2011","journal-title":"Dev Med Child Neurol"},{"key":"10.3233\/JND-210689_ref36","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/dmcn.12220","article-title":"Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy","volume":"55","author":"Mayhew","year":"2013","journal-title":"Dev Med Child Neurol"},{"key":"10.3233\/JND-210689_ref37","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.0b013e318225ab2e","article-title":"Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study","volume":"77","author":"Mazzone","year":"2011","journal-title":"Neurology"},{"key":"10.3233\/JND-210689_ref38","doi-asserted-by":"crossref","first-page":"e108205","DOI":"10.1371\/journal.pone.0108205","article-title":"Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes","volume":"9","author":"Pane","year":"2014","journal-title":"PLoS One"},{"key":"10.3233\/JND-210689_ref39","first-page":"149","article-title":"The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials","volume":"87","author":"Ricotti","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JND-210689_ref40","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.pediatrneurol.2008.08.006","article-title":"High incidence of electrocardiogram abnormalities in young patients with duchenne muscular dystrophy","volume":"39","author":"Takami","year":"2008","journal-title":"Pediatr Neurol"},{"key":"10.3233\/JND-210689_ref41","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1542\/peds.2010-0929","article-title":"Serum transaminase levels in boys with Duchenne and Becker muscular dystrophy","volume":"127","author":"McMillan","year":"2011","journal-title":"Pediatrics"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JND-210689","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:49:45Z","timestamp":1777506585000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JND-210689"}},"subtitle":[],"editor":[{"given":"Virginia","family":"Arechavala-Gomeza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Annemieke","family":"Aartsma-Rus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":38,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.3233\/jnd-210689","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,14]]}}}